Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.24% |
| Dec 31, 2025 | -51.99% |
| Sep 30, 2025 | -30.43% |
| Jun 30, 2025 | 21.79% |
| Mar 31, 2025 | 15.60% |
| Dec 31, 2024 | -13.89% |
| Sep 30, 2024 | 16.66% |
| Jun 30, 2024 | -3.89% |
| Mar 31, 2024 | -5.42% |
| Dec 31, 2023 | -1.55% |
| Sep 30, 2023 | -25.06% |
| Jun 30, 2023 | -1.12% |
| Mar 31, 2023 | -19.69% |
| Dec 31, 2022 | 24.62% |
| Sep 30, 2022 | -42.81% |
| Jun 30, 2022 | -39.35% |
| Mar 31, 2022 | -42.52% |
| Dec 31, 2021 | -13.66% |
| Sep 30, 2021 | -23.97% |
| Jun 30, 2021 | -10.69% |
| Mar 31, 2021 | -17.58% |
| Dec 31, 2020 | 23.16% |
| Sep 30, 2020 | 16.56% |
| Jun 30, 2020 | -5.80% |
| Mar 31, 2020 | -4.97% |
| Dec 31, 2019 | 17.75% |
| Sep 30, 2019 | -19.89% |
| Jun 30, 2019 | -1.91% |
| Mar 31, 2019 | -18.51% |
| Dec 31, 2018 | -32.23% |
| Sep 30, 2018 | -15.06% |
| Jun 30, 2018 | -23.44% |
| Mar 31, 2018 | -6.12% |
| Dec 31, 2017 | -21.71% |
| Sep 30, 2017 | -9.89% |
| Jun 30, 2017 | -4.97% |
| Mar 31, 2017 | 6.12% |
| Dec 31, 2016 | -20.52% |
| Sep 30, 2016 | 2.35% |
| Jun 30, 2016 | -4.87% |
| Mar 31, 2016 | 1.06% |
| Dec 31, 2015 | -19.09% |
| Sep 30, 2015 | -11.77% |
| Jun 30, 2015 | -14.69% |